FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304095> ?p ?o ?g. }

• W4367304095 abstract "<h3>Objective:</h3> To evaluate the long-term efficacy of satralizumab in patients with AQP4-IgG+ NMOSD. <h3>Background:</h3> Satralizumab reduced the risk of protocol-defined relapse (PDR) and severe PDR vs placebo in the double-blind periods (DBP) of two phase 3 trials in patients with NMOSD: SAkuraSky (NCT02028884; satralizumab + baseline immunosuppressants [IST]) and SAkuraStar (NCT02073279; satralizumab monotherapy). <h3>Design/Methods:</h3> Patients who completed the DBPs and open-label extensions (OLEs) of SAkuraSky and SAkuraStar were rolled-over into a single-arm, open-label study (SAkuraMoon [NCT04660539]) and continued receiving satralizumab 120mg Q4W +/− IST; we evaluated all AQP4-IgG+ adults (≥18 years) who received ≥1 dose of satralizumab during these studies (data cut-off: 31 January 2022). PDRs in the DBPs were adjudicated by a Clinical Endpoint Committee; however, PDRs in the OLEs and SAkuraMoon were determined by the investigator (iPDRs). We evaluated the annualized iPDR rate (ARR), time to first iPDR, severe iPDR (≥2 point increase in the Expanded Disability Status Scale [EDSS] score), and sustained EDSS worsening (EDSS increase of ≥2, ≥1, or ≥0.5 points for patients with baseline scores of 0, 1–5, or ≥5.5, respectively, confirmed ≥24 weeks post-initial-worsening). <h3>Results:</h3> Overall, 106 AQP4-IgG+ adults were included. The median (range) duration of satralizumab exposure was 5.0 (0.1–7.9) years. The overall adjusted ARR (95% CI) was 0.09 (0.06–0.12). When assessed longitudinally, the ARR did not increase with additional years of exposure (Y1: 0.16 [0.09–0.27]; Y2: 0.10 [0.05–0.20]; Y3: 0.05 [0.01–0.15]; Y4: 0.07 [0.02–0.26]). At Week 240 (4.6 years), 72% (95% CI: 62–80%) of satralizumab-treated patients were free from iPDR, 91% (84–96%) were free from severe iPDR, and 85% (75–91%) had no sustained EDSS worsening. <h3>Conclusions:</h3> These results demonstrate that the efficacy of satralizumab observed in the DBPs is sustained with long-term treatment. High proportions of patients remained free from relapse, severe relapse, or worsening disability, with a consistently low ARR over 4.6 years of satralizumab exposure. <b>Disclosure:</b> Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Genzyme. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Ingo Kleiter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Almirall. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck Serono, Medimmune, Argenx, Janssen, Mitsubushi, UCB, Roche, Novartis, Amplo, Alexion, Chugai, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx, Sanofi. Dr. Palace has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche, UCB, Alexion, Chugai. Dr. Palace has stock in Astra Zenica. The institution of Dr. Palace has received research support from Roche, AMPLO, Alexion, UCB,.Meddimune, . Dr. Palace has received intellectual property interests from a discovery or technology relating to health care. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Boipharma. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Japan Tobacco. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi-Tanabe. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chugai. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Fujihara has received research support from Ministry of Health, Welfare and Labor of Japan. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a speaker, chair, etc with Novartis. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving as a speaker, chair, etc with Biogen. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a speaker, chair, etc with Mitsubishi-Tanabe. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a apeaker, chair, etc with Chugai. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a speaker, chair, etc with Alexion. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a chair, speaker with Asahi Kasei Medical. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker with Eisai. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker, chair with Teijin. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving as a speaker with Roche. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janseen. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Albert Saiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Vodopivec has received personal compensation for serving as an employee of Roche. An immediate family member of Dr. Vodopivec has received personal compensation for serving as an employee of Novartis. Dr. Vodopivec has stock in Roche. Gaelle Klingelschmitt, 17039 has received personal compensation for serving as an employee of F.Hoffmann-La Roche LTD. Carole Marcillat has received personal compensation for serving as an employee of Hoffmann La Roche. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon Therapeutics. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Bio. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Antigenomycs. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chugai. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MedEdicus. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ImCyse. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Podoll. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Patterson. The institution of Dr. Bennett has received research support from Novartis. The institution of Dr. Bennett has received research support from Alexion. Dr. Bennett has received intellectual property interests from a discovery or technology relating to health care. Dr. Bennett has received publishing royalties from a publication relating to health care." @default.
• W4367304095 created "2023-04-29" @default.
• W4367304095 creator A5008016806 @default.
• W4367304095 creator A5016397545 @default.
• W4367304095 creator A5023960883 @default.
• W4367304095 creator A5030980805 @default.
• W4367304095 creator A5045915531 @default.
• W4367304095 creator A5067260539 @default.
• W4367304095 creator A5070021548 @default.
• W4367304095 creator A5072712902 @default.
• W4367304095 creator A5087379536 @default.
• W4367304095 date "2023-04-25" @default.
• W4367304095 modified "2023-10-09" @default.
• W4367304095 title "Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (S5.001)" @default.
• W4367304095 doi "https://doi.org/10.1212/wnl.0000000000202535" @default.
• W4367304095 hasPublicationYear "2023" @default.
• W4367304095 type Work @default.
• W4367304095 citedByCount "0" @default.
• W4367304095 crossrefType "proceedings-article" @default.
• W4367304095 hasAuthorship W4367304095A5008016806 @default.
• W4367304095 hasAuthorship W4367304095A5016397545 @default.
• W4367304095 hasAuthorship W4367304095A5023960883 @default.
• W4367304095 hasAuthorship W4367304095A5030980805 @default.
• W4367304095 hasAuthorship W4367304095A5045915531 @default.
• W4367304095 hasAuthorship W4367304095A5067260539 @default.
• W4367304095 hasAuthorship W4367304095A5070021548 @default.
• W4367304095 hasAuthorship W4367304095A5072712902 @default.
• W4367304095 hasAuthorship W4367304095A5087379536 @default.
• W4367304095 hasConcept C118552586 @default.
• W4367304095 hasConcept C121332964 @default.
• W4367304095 hasConcept C126322002 @default.
• W4367304095 hasConcept C15755913 @default.
• W4367304095 hasConcept C159654299 @default.
• W4367304095 hasConcept C203014093 @default.
• W4367304095 hasConcept C2777154362 @default.
• W4367304095 hasConcept C2780898057 @default.
• W4367304095 hasConcept C2781137167 @default.
• W4367304095 hasConcept C61797465 @default.
• W4367304095 hasConcept C62520636 @default.
• W4367304095 hasConcept C71924100 @default.
• W4367304095 hasConceptScore W4367304095C118552586 @default.
• W4367304095 hasConceptScore W4367304095C121332964 @default.
• W4367304095 hasConceptScore W4367304095C126322002 @default.
• W4367304095 hasConceptScore W4367304095C15755913 @default.
• W4367304095 hasConceptScore W4367304095C159654299 @default.
• W4367304095 hasConceptScore W4367304095C203014093 @default.
• W4367304095 hasConceptScore W4367304095C2777154362 @default.
• W4367304095 hasConceptScore W4367304095C2780898057 @default.
• W4367304095 hasConceptScore W4367304095C2781137167 @default.
• W4367304095 hasConceptScore W4367304095C61797465 @default.
• W4367304095 hasConceptScore W4367304095C62520636 @default.
• W4367304095 hasConceptScore W4367304095C71924100 @default.
• W4367304095 hasLocation W43673040951 @default.
• W4367304095 hasOpenAccess W4367304095 @default.
• W4367304095 hasPrimaryLocation W43673040951 @default.
• W4367304095 hasRelatedWork W1989157476 @default.
• W4367304095 hasRelatedWork W2177942776 @default.
• W4367304095 hasRelatedWork W2893722437 @default.
• W4367304095 hasRelatedWork W2901982610 @default.
• W4367304095 hasRelatedWork W2955486649 @default.
• W4367304095 hasRelatedWork W2985874027 @default.
• W4367304095 hasRelatedWork W3021383097 @default.
• W4367304095 hasRelatedWork W3089862412 @default.
• W4367304095 hasRelatedWork W3138075888 @default.
• W4367304095 hasRelatedWork W3206939395 @default.
• W4367304095 isParatext "false" @default.
• W4367304095 isRetracted "false" @default.
• W4367304095 workType "article" @default.